Analyst Daniel Brennan of TD Cowen reiterated a Buy rating on GeneDx Holdings (WGS – Research Report), reducing the price target to $110.00.
Daniel Brennan has given his Buy rating due to a combination of factors including the solid execution by GeneDx Holdings and the potential for growth in underpenetrated markets. Despite a recent decline in stock price following a first-quarter performance that exceeded expectations, the company has shown strong gross margins and net income results, which are promising for future performance.
Furthermore, the management’s decision to raise the full-year 2025 guidance reflects confidence in the company’s growth trajectory, supported by the acquisition of Fabric Genomics. The total revenue and volume growth, although slightly below management’s guidance, still demonstrate significant year-over-year increases, reinforcing the positive long-term outlook for the company.
In another report released today, Craig-Hallum also reiterated a Buy rating on the stock with a $114.00 price target.